Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huperzine A for MCI due to Alzheimer's Disease
NCT02931136Phase 4Not yet recruiting
- Sponsor
- Shanghai Mental Health Center
- Start
- Nov 2019
- Primary completion
- Dec 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Huperzine A in Alzheimer's disease (AD), sponsored by Shanghai Mental Health Center. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
Huperzine A
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02931136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02931136.